DNA methylation estimates of immune cell abundance have prognostic potential in triple negative breast cancer
Immune infiltration is now recognised as an important prognostic factor in triple negative breast cancer (TNBC). DNA methylation, due to its cell-type specificity, offers a promising approach for quantifying immune cell abundance as a biomarker for risk stratification. Here, we used EpiDISH, a DNA methylation-based cellular deconvolution method, to estimate immune cell proportions from genome-wide methylation data across four independent breast cancer datasets. We show that increased methylation-estimated immune cell percentage in TNBC patients is associated with improved outcomes. This highlights the potential of DNA methylation-based estimates of cell composition for prognosis in TNBC.
Authors
- Matt Trau (ORCID: https://orcid.org/0000-0001-5516-1280)
- Braydon Ashley Meyer
- Ruth Pidsley
- Kelly A. Avery-Kiejda
- Melissa C. Southey
- Sarah Williams
- Susan J. Clark
- Clare Stirzaker
- Pierre-Antoine Dugué
- Darren Korbie
- Roger L. Milne
- Rodney J. Scott
Institutions
- New South Wales Department of Health (AU)
- Garvan Institute of Medical Research (AU)
- The University of Queensland (AU)
- The University of Melbourne (AU)
- Cancer Council Victoria (AU)
- UNSW Sydney (AU)
- Hunter Medical Research Institute (AU)
- St Vincent's Clinic (AU)
- Monash University (AU)
- University of Newcastle Australia (AU)
Publication Details
- Journal
- Clinical Epigenetics
- Published
- 2026-01-27
- DOI
- https://doi.org/10.1186/s13148-026-02052-w
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 0.00